e-learning
resources
Vienna 2009
Monday, 14.09.2009
Biological and clinical markers in lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
EGFR and hTERT expression in high risk COPD patients – clinical application
R. Cherneva, O. Georgiev, D. Petrova, D. Petrov, D. Toncheva (Sofia, Bulgaria)
Source:
Annual Congress 2009 - Biological and clinical markers in lung cancer
Session:
Biological and clinical markers in lung cancer
Session type:
Thematic Poster Session
Number:
2674
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Cherneva, O. Georgiev, D. Petrova, D. Petrov, D. Toncheva (Sofia, Bulgaria). EGFR and hTERT expression in high risk COPD patients – clinical application. Eur Respir J 2009; 34: Suppl. 53, 2674
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
EGFR
and
hTERT
mRNA expression in non-small cell lung cancer patients – Diagnostic and prognostic implications
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
COPD prevalence in lung cancer patients – Is COPD a risk factor for lung cancer?
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
Soluble NKG2D ligand expression associates with smoking, presence of COPD, and presence of lung cancer: The "EMICON" study
Source: Annual Congress 2010 - Lung morbidity on exposure to various agents
Year: 2010
IL1RL1
polymorphisms are associated with the level of soluble
IL1RL1
and asthma development in children
Source: Annual Congress 2009 - Asthma genetics: from genome wide to single nucleotide polymorphisms
Year: 2009
The VE/VCO
2
slope as a factor associated with the health status in patients with COPD
Source: Annual Congress 2012 - Outcomes and assessment methods in physiotherapy and rehabilitation
Year: 2012
Tissue expression of alpha crystallins and plasma levels of antibodies against them in NSCLC patients – Prognostic significance
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
Smoking, genotype and gene expression levels in COPD
Source: International Congress 2014 – Personalised exposure and gene environment interactions in chronic airway disease: the exposome and epigenome
Year: 2014
Role of
-511C>T/+3953C>T
haplotypes of
IL1B
gene as risk factors of COPD
Source: Annual Congress 2012 - Recent progress in mechanisms and diagnostics of COPD and asthma
Year: 2012
TTF-1 in advanced SCLC – Diagnostic and prognostic relevance
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011
COPD screening and risk factor frequency identification study
Source: Annual Congress 2013 –Disease control and quality of life in airway diseases
Year: 2013
EGFR – a useful biomarker?
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
Characteristics and prognostic relevance of
p
53 gene mutations in Polish non small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2005; 26: Suppl. 49, 92s
Year: 2005
Impact of age in the clinical expression of COPD
Source: Annual Congress 2008 - COPD in the elderly - quality of life and scores in COPD
Year: 2008
The nuclear expression of the small heat shock protein – alpha B crystalline as a marker for poor prognosis in NSCLC patients
Source: Annual Congress 2009 - Basic science and lung cancer
Year: 2009
Inhibitor of DNA-binding (Id) – 1 and 3 proteins overexpression has impact on prognosis of lung adenocarcinoma
Source: Annual Congress 2011 - Progress in pathology of lung cancer
Year: 2011
Imbalances in TNFα in patients with a TNFα polymorphism and a COPD phenotype
Source: Annual Congress 2009 - New results in molecular pathology and functional genomics of non-neoplastic lung diseases
Year: 2009
BAMBI – A TGF-β pseudoreceptor with possible functional involvement in COPD and NTHI infection
Source: Annual Congress 2011 - Molecular: pathology of infectious and inflammatory lung disease
Year: 2011
Identifying a ‘frequent exacerbator‘ phenotype in a cohort of COPD patients (EXACO study)
Source: Annual Congress 2012 - Prevalences and characterstics of obstructive airway disease
Year: 2012
High levels of serum cholesterol – protective and predictive factor for activation of tuberculosis; practical considerations
Source: Annual Congress 2009 - Pulmonary infections
Year: 2009
Studies on clinical significance and relationship with PI and gene protein expression of p16, Rb and Cyclin-D1 in lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 230s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept